Techniques for purposing a new compound and for re-purposing a drug

• US 8,489,336 B2
• Filed: 11/18/2009
• Issued: 07/16/2013
• Est. Priority Date: 09/16/2002
• Status: Expired due to Fees

• Current Assignee: Optimata Ltd.
• Original Assignee: Optimata Ltd.
• Inventors: Arakelyan, Levon, Selitser, Vera, Agur, Zvia, Eilam Tzoreff, Tali
• Primary Examiner(s): Clow, Lori A
• Application Number:
  US12/621,175
• Publication Number:
  US 20100161301A1
• Time in Patent Office: 1,336 Days
• Field of Search: None
• US Class Current: 702/19
• CPC Class Codes: G16C 20/30 Prediction of properties of chemical compounds, compositions or mixtures

Abstract

A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed.

Claims

1. A method for repurposing a pharmaceutical compound, resulting in a new treatment protocol to salvage a failed drug or an approved drug, the method comprising:

a) identifying a pharmaceutical compound, wherein the pharmaceutical compound is a drug that has failed in clinical development or an approved drug;

b) creating a computer model for pharmacokinetics and pharmacodynamics of the drug from in vitro or in vivo data obtained from administration of at least a single dose of the drug of (a) from a pre-clinical trial wherein the computer model created is adjusted based on data from in vitro or in vivo studies in animals;

c) performing computer simulations using the computer model with data obtained from administration of different doses of the drug and dosing intervals for different indications and patient populations in at least one phase I clinical trial;

wherein the computer model is an in silico patient that is adjusted according to results of the pre-clinical trial or the at least one phase I clinical trial.

2. The method of claim 1, wherein the new treatment protocol is based on at least one component selected from the group consisting of new regimen, new drug combination, new disease, new patient population, and use of biomarkers represented in the computer model to differentiate between responders and non-responders in the patient population.

3. The method of claim 2, wherein the new disease is cancer.

4. The method of claim 2, wherein the new disease is a hematological disorder.

5. The method of claim 2, wherein the new disease is a hematological disorder that is related to cancer.

6. The method of claim 1, wherein the new treatment protocol reduces drug toxicity.

7. The method of claim 1, wherein the new treatment protocol increases drug efficacy.

8. The method of claim 1, wherein the new treatment protocol increases drug efficacy and reduces drug toxicity.

9. The method of claim 1, wherein in step (c), the computer simulations of the model are performed prior to the phase I clinical trial, to obtain predicted phase I clinical trial results which are compared to the phase I clinical trial results and the computer model is adjusted based on the comparison.

10. The method of claim 1, wherein the different doses of the drug of step (c) are incrementally increased in at least one dose escalation step.

11. The method of claim 10, wherein the dose escalation step is calculated by computer simulations performed using the computer model in step (b) to obtain a maximal tolerated dose, minimum effective dose, and a recommended dose.

12. The method of claim 1, wherein the computer model is adjusted based on whether the clinical trial indicates a result higher than a threshold in at least one of pre-clinical trial and phase I clinical trial.

13. A method for repurposing a pharmaceutical compound, resulting in a new treatment protocol to salvage a failed drug or an approved drug, the method comprising

creating a computer model for pharmacokinetics and pharmacodynamics of a drug that has failed in clinical development or an approved drug from in vitro or in vivo data obtained from administration of at least a single dose of the drug from at least one clinical trial to predict one or more clinical outcomes;

wherein the prediction of one or more clinical outcomes is compared with clinical results from at least one clinical trial and the comparison is used to adjust the computer model,

wherein the computer model is an in silico patient that is adjusted according to the clinical results at least from at least one pre-clinical trial; and

wherein a new treatment protocol to salvage the failed drug or the approved drug is determined based on computer simulation results.

14. The method of claim 13, wherein the clinical results from at least one clinical trial is further selected from the group consisting of pre-clinical trial, phase I clinical trial, phase II clinical trial, phase III clinical trial, and phase IV clinical trial.

15. A method for repurposing a pharmaceutical compound, resulting in a new treatment protocol to salvage a failed drug or an approved drug, the method comprising

creating a computer model for pharmacokinetics and pharmacodynamics of a drug that has failed in clinical development or an approved drug from in vitro or in vivo data obtained from administration of at least a single dose of the drug from at least one clinical trial to predict one or more clinical outcomes;

wherein the prediction of one or more clinical outcomes is compared with clinical results from at least one clinical trial and the comparison is used to adjust the computer model, wherein the computer model is an in silico patient that is adjusted according to the clinical results at least from at least one phase I clinical trial; and

wherein a new treatment protocol to salvage the failed drug or the approved drug is determined based on results of the computer simulation predictions.

16. The method of claim 15, wherein the at least a single dose is administered in a dose-escalation during phase I clinical trial.

17. The method of claim 15, wherein the clinical results from at least one clinical trial is further selected from the group consisting of pre-clinical trial, phase I clinical trial, phase II clinical trial, phase III clinical trial, and phase IV clinical trial.

18. A method for repurposing a pharmaceutical compound, resulting in a new treatment protocol to salvage a failed drug or an approved drug, the method comprising

creating a computer model for pharmacokinetics and pharmacodynamics of a drug that has failed in clinical development or an approved drug from in vitro or in vivo data obtained from administration of at least a single dose of the drug from at least one clinical trial to predict one or more clinical outcomes;

wherein the prediction of one or more clinical outcomes is compared with clinical results from at least one clinical trial and the comparison is used to adjust the computer model, wherein the computer model is an in silico patient that is adjusted according to the clinical results at least from at least phase II clinical trial; and

wherein a new treatment protocol to salvage the failed drug or the approved drug is determined based on the computer simulation results.

19. The method of claim 18, wherein the clinical results from at least one clinical trial is further selected from the group consisting of pre-clinical trial, phase I clinical trial, phase II clinical trial, phase III clinical trial, and phase IV clinical trial.

20. A method for repurposing a pharmaceutical compound, resulting in a new treatment protocol to salvage a failed drug or an approved drug, the method comprising

creating a computer model for pharmacokinetics and pharmacodynamics of a drug that has failed in clinical development or an approved drug from in vitro or in vivo data obtained from administration of at least a single dose of the drug from at least one clinical trial to predict one or more clinical outcomes;

wherein the prediction of one or more clinical outcomes is compared with clinical results from at least one clinical trial and the comparison is used to adjust the computer model, wherein the computer model is an in silico patient that is adjusted according to the clinical results at least from at least one phase III clinical trial; and

wherein a new treatment protocol to salvage the failed drug or the approved drug is determined based on the computer simulation results.

21. The method of claim 20, wherein the clinical results from at least one clinical trial is further selected from the group consisting of pre-clinical trial, phase I clinical trial, phase II clinical trial, phase III clinical trial, and phase IV clinical trial.

22. A method for repurposing a pharmaceutical compound, resulting in a new treatment protocol to salvage a failed drug or an approved drug, the method comprising

creating a computer model for pharmacokinetics and pharmacodynamics of a drug that has failed in clinical development or an approved drug from in vitro or in vivo data obtained from administration of at least a single dose of the drug from at least one clinical trial to predict post-marketing efficacy of the drug, and long term efficacy of the drug, resulting in prediction of one or more clinical outcomes;

wherein the prediction of one or more clinical outcomes is compared with clinical results from at least one clinical trial and the comparison is used to adjust the computer model, wherein the computer model is an in silico patient that is adjusted according to the clinical results at least from at least one phase IV clinical trial; and

wherein a new treatment protocol to salvage the failed drug or the approved drug is determined based on the computer simulation results.

23. The method of claim 22, wherein the clinical results from at least one clinical trial is further selected from the group consisting of pre-clinical trial, phase I clinical trial, phase II clinical trial, phase III clinical trial, and phase IV clinical trial.

24. A system for repurposing a pharmaceutical compound, the system comprising:

identifying a pharmaceutical compound, wherein the pharmaceutical compound is a drug that has failed in clinical development or an approved drug;

a computer model for pharmacokinetics and pharmacodynamics of the drug is created based on data of effects of the drug administered in vitro or in vivo to determine the physiological effect of the drug on a disease;

a model adjustor that adjusts the computer model based upon results of computer simulations from at least one pre-clinical or at least one clinical trial;

a treatment protocol generator that determines a new treatment protocol to salvage the drug that has failed in a clinical development or the approved drug.

25. The system of claim 24, wherein the new treatment protocol is based on at least one component selected from the group consisting of new regimen, new drug combination, new disease, new patient population, and use of biomarkers represented in the computer model to differentiate between responders and non-responders in the patient population.

26. The system of claim 24, wherein the new treatment protocol is a drug combination.

27. The system of claim 24, wherein the new disease is cancer.

28. The system of claim 24, wherein the new disease is a hematological disorder.

29. The system of claim 24, wherein the new disease is a hematological disorder that is related to cancer.

30. The system of claim 24, wherein the new treatment protocol reduces drug toxicity.

31. The system of claim 24, wherein the new treatment protocol increases drug efficacy.

32. The system of claim 24, wherein the new treatment protocol increases drug efficacy and reduces drug toxicity.

33. A computer program product comprising a non-transitory computer readable media having instructions that allows a computer to implement a process comprising:

a) identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug;

b) creating a computer model for pharmacokinetics and pharmacodynamics of the drug based on data of effects of the drug administered in vitro or in vivo to determine the physiological effect of the drug on a disease;

c) adjusting the computer model based upon results of computer simulations from at least one pre-clinical or at least one clinical trial;

d) determining a new treatment protocol to salvage the failed drug or the approved drug based on the results of computer simulation results; and

e) displaying the new treatment protocol in an output window.